KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Current Deferred Revenue for 8 consecutive years, with $46.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 44.3% to $46.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.2 million through Dec 2025, down 44.3% year-over-year, with the annual reading at $46.2 million for FY2025, 44.3% down from the prior year.
  • Current Deferred Revenue hit $46.2 million in Q4 2025 for Adaptive Biotechnologies, up from $41.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $168.4 million in Q1 2022 to a low of $41.3 million in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $84.8 million across 5 years, with a median of $81.9 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 114.94% in 2022 and later crashed 64.18% in 2023.
  • Year by year, Current Deferred Revenue stood at $80.5 million in 2021, then surged by 52.52% to $122.7 million in 2022, then decreased by 23.87% to $93.4 million in 2023, then fell by 11.22% to $82.9 million in 2024, then crashed by 44.3% to $46.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ADPT at $46.2 million in Q4 2025, $41.3 million in Q3 2025, and $55.3 million in Q2 2025.